CRAC
Calcium channels have long been the target of therapeutic drugs aimed at treating the symptoms of cardiovascular disease and migraine headache. They regulate the permeability of the cell membrane towards calcium. Axon Medchem offers pharmacological standards that interact at each of the 2 main classes within the family of calcium channels, the voltage-gated, and the ligand-gated channels.[1].
[1] InternationalUnion of Pharmacology. XLVIII. Nomenclature and Structure-Function Relationships of Voltage-Gated Calcium Channels. WA Catterall, E Perez-Reyes, TP Snutch, J Striessnig. Pharmacol Rev 57:411–425, 2005
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 4066 | CM-4620 | Selective Orai1 channel inhibitor; SOCE inhibitor | €150.00 | |
| 1868 | CRAC inhibitor 44 | Potent and selective CRAC ion channel blocker | €110.00 | |